IP Library Granted Patent US 10,166,313
Granted Patent B2
US 10,166,313 · App. 15/024,520 · Granted Jan 1, 2019

Medical or dental material for osteogenesis

Inventors: Tadao Fukushima (Fukuoka, JP); Jun Yamazaki (Fukuoka, JP); Jun Ohno (Fukuoka, JP); Masako Toda (Fukuoka, JP); Makoto Mitarai (Ibaraki, JP); Keishi Iohara (Ibaraki, JP)
Assignee: MARUHA NICHIRO CORPORATION
A61L27/26A61K6/0082A61K6/08A61K6/097A61L27/12A61L27/54A61L2300/252A61L2300/258A61L2300/414A61L2400/06A61L2430/02A61L2430/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,313
App. No.
15/024,520
Granted
Jan 1, 2019
Kind
B2
Abstract

A bone-repairing agent excellent in workability and applicability to clinical surgical techniques and having a drastically enhanced bone formation rate, obtained by including an elastin hydrolysate in a complex of DNA and at least one selected from the group consisting of protamine, a protamine derivative, and a protamine hydrolysate can be provided. A medical or dental material for bone formation using this bone-repairing agent can be provided.

Claims (12)

1. A medical or dental material for osteogenesis, comprising a DNA/protamine/elastin complex, as an active ingredient for bone formation, comprising:

(1) DNA;

(2) at least one protamine compound selected from the group consisting of protamine, a protamine derivative, and a prolamine hydrolysate; and

(3) an enzymatic degradation product of elastin having a molecular weight ranging from 350 to 3,600 Da; wherein the DNA and the at least one protamine compound form a DNA/protamine complex and the enzymatic degradation product of elastin is incorporated into the DNA/protamine complex to form the DNA/protamine/elastin complex; wherein the ratio of the DNA and the at least one protamine compound is from about 1:9 to about 9:1 by weight; and wherein about 1 to about 75 parts by weight for the enzymatic degradation product of elastin is blended with about 100 parts by weight of the DNA/protamine complex.

2. The medical or dental material according to claim 1 , wherein a further medicinal ingredient is trapped by intercalation and/or groove binding within the DNA.

3. The medical or dental material according to claim 1 , wherein a bone formation factor or a growth factor is carried.

4. The medical or dental material according to claim 1 , wherein the material comprises calcium phosphate.

5. The medical or dental material according to claim 1 , wherein the complex has formability enabling injection of the material to an area of bone loss or an area of alveolar bone loss.

6. The medical or dental material according to claim 1 , wherein the ratio of the DNA and the at least one protamine compound is from about 1:1 to about 1:1.5 by weight.

7. The medical or dental material according to claim 1 , wherein about 20 to about 50 parts by weight of the enzymatic degradation product of elastin is blended with about 100 parts by weight of the DNA/protamine complex.

8. The medical or dental material according to claim 1 , wherein about 50 parts by weight of the enzymatic degradation product of elastin is blended with about 100 parts by weight of the DNA/protamine complex.

9. The medical or dental material according to claim 1 , wherein the elastin is a cardiac bulbus arteriosus elastin of a fish, a cow, or a pig.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2016
From: FUKUSHIMA, TADAO; YAMAZAKI, JUN; OHNO, JUN; TODA, MASAKO; MITARAI, MAKOTO; IOHARA, KEISHI
To: MARUHA NICHIRO CORPORATION
Reel/Frame 038091/0756 →
Continuity (1)
Related Publication 20160235888A1 · Aug 18, 2016